Transce3nd LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Transce3nd LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2,850.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,593 shares of the medical research company's stock after purchasing an additional 1,539 shares during the quarter. Transce3nd LLC's holdings in IQVIA were worth $280,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC lifted its stake in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after acquiring an additional 2,537 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in IQVIA by 0.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,104 shares of the medical research company's stock valued at $5,130,000 after acquiring an additional 157 shares in the last quarter. Cibc World Markets Corp lifted its stake in IQVIA by 15.0% in the 4th quarter. Cibc World Markets Corp now owns 27,629 shares of the medical research company's stock valued at $5,429,000 after acquiring an additional 3,604 shares in the last quarter. Signaturefd LLC raised its stake in shares of IQVIA by 13.6% during the 4th quarter. Signaturefd LLC now owns 2,894 shares of the medical research company's stock worth $569,000 after purchasing an additional 346 shares in the last quarter. Finally, Generali Asset Management SPA SGR bought a new stake in shares of IQVIA during the 4th quarter worth approximately $2,004,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.5%

NYSE IQV traded down $2.37 during trading hours on Friday, hitting $160.88. 2,312,787 shares of the company's stock were exchanged, compared to its average volume of 1,675,737. The stock has a 50-day simple moving average of $152.90 and a 200 day simple moving average of $170.85. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The firm has a market cap of $27.83 billion, a price-to-earnings ratio of 21.92, a PEG ratio of 1.81 and a beta of 1.30. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company posted $2.54 earnings per share. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Robert W. Baird dropped their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Truist Financial dropped their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Evercore ISI boosted their target price on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. UBS Group decreased their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $222.45.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.